Rett syndrome (RTT) is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding MeCP2, an epigenetic modulator that binds the methyl CpG dinucleotide in target genes to regulate transcription. Previously we and others reported a role of microglia in the pathophysiology of RTT. Because microglia in the Mecp2 knockout (Mecp2KO) mouse model of RTT over-produce neurotoxic mediators glutamate and reactive oxygen species, we hypothesize that blocking neuron-microglia interaction by ablation of CX 3 CR1, a chemokine receptor expressed in microglia/myeloid cells mediating such interaction by pairing with its neuronal ligand CX 3 CL1, would ameliorate the RTT-like phenotype in Mecp2KO mice. Here we report that CX 3 CR1 ablation prolonged the lifespan of Mecp2KO mice from a median survival of 54.5-74 days, and significantly improved the body weight gain, symptomatic scores, major respiratory parameters, and motor coordination and performance. CX 3 CR1 ablation rectified previously identified histological abnormalities in the Mecp2KO brain such as neuronal soma size in hippocampal CA2, and the number, soma size, and process complexity of microglia. Moreover, CX 3 CR1 ablation enhanced the neurotrophic action of microglia in Mecp2KO mice by producing higher amount of insulin-like growth factor 1. Our data support a role of myeloid cells/microglia in RTT and suggest a novel therapeutic approach for RTT by targeting CX 3 CR1 with specific antagonists or genetic downregulation.
Introduction
Rett syndrome (RTT) is caused by loss-of-function mutations in the X-linked gene encoding the epigenetic regulator MeCP2. RTT is a prototype of postnatal neurodevelopmental disorders affecting synaptic plasticity, and shares common mechanisms with autism (Zoghbi, 2003) . RTT primarily affects young girls (Mecp2-/+), who develop normally until six to 18 months of age, when they start to regress, showing deceleration of brain growth, loss of motor skills including purposeful hand movements, ataxia, loss of vocalization skills, loss of cognitive capability, autistic features, seizures, and respiratory dysfunction (Chahrour and Zoghbi, 2007) .
The absence of MeCP2, which ''reads" DNA methylation marks, blocks the effective recognition and execution of epigenetic codes, resulting in altered gene expression and cellular function (Chahrour et al., 2008) . Although such biochemical function of MeCP2 is well delineated, the specific mutant-driven toxic mechanisms that initiate and promote progression of RTT remain unclear. Deletion of Mecp2 in neuronal populations led to RTT-like pathology in mice (Chen et al., 2001; Chao et al., 2010) , suggesting an initiating role of neuronal MeCP2 deficiency, although such neuron-driven phenotype was partial and mild. Interestingly, recovering wild-type (WT) Mecp2 in astrocytes or microglia/myeloid cells in the Mecp2 knockout (Mecp2KO) model of RTT arrested RTT-like pathology, suggesting that dysfunction of non-neuronal cells contributes to progression of disease (Lioy et al., 2011; Derecki et al., 2013; Cronk et al., 2015a) . In contrast, neuronal re-expression of WT Mecp2 in Mecp2KO mice failed to rescue RTT-like phenotype (Alvarez-Saavedra et al., 2007) . Taken together, the RTT pathology appears to result from contributions from different cell types and may in large part depend on neuron-glia interactions.
Myeloid cells and brain resident microglia appear to play a significant role in RTT (Maezawa and Jin, 2010; Derecki et al., 2012; Cronk et al., 2015b; Jin et al., 2015) . Remarkably, Mecp2KO mice, which usually die at 9-10 weeks, became almost normal and some lived to nearly one year after their brains were populated with WT peripherally-derived resident CNS macrophages by a bone-marrow transplant approach. When cranial irradiation was blocked to prevent microglial engraftment, disease was not
